Research and Markets: Pediatrics Partnering Terms and Agreements

The Pediatrics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pediatrics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter pediatrics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pediatrics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual pediatrics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in pediatrics dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading pediatrics deals since 2007.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of pediatrics deals, as well as contract documents available in the public domain.

Chapter 5 provides comprehensive access to all pediatrics deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities.

Chapter 6 provides a comprehensive directory of all pediatrics partnering deals signed and announced since 2007. The chapter is organized by specific pediatrics therapy focus.

In addition, a comprehensive appendix is provided with each report of all pediatrics partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in pediatrics partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of pediatrics technologies and products.

– Abbott

– Allergan

– AstraZeneca

– Baxter International

– Biogen Idec

– Bristol-Myers Squibb

– Daiichi Sankyo

– Eisai

– Forest Laboratories

– GlaxoSmithKline

– Johnson & Johnson

– Merck & Co

– Merck KGaA

– Mitsubishi Tanabe

– Novartis

– Novo Nordisk

– Pfizer

– Roche

– Sanofi

– Shionogi

– Teva